当科のご案内

2018年研究業績

  1. Kieffer T, Woltjen J, Osafune K, Yabe D, Inagaki N. Beta-cell replacement strategies for diabetes. J Diabetes Investig. 9(3):457-463, 2018. (doi: 10.1111/jdi.12758)
  2. Haneda M, Noda M, Origasa H, Noto H, Yabe D, Fujita Y, Goto A, Kondo T, Araki E. Japanese Clinical Practice Guideline for Diabetes 2016. J Diabetes Investig. 9(3): 657 697, 2018. ( doi: 10.1111/jdi.12810)
  3. Yabe D, Seino Y, Seino Y. The incretin concept revised: The origin of GLP-1’s insulinotropic function-the gut, the islets or both? J Diabetes Investig. 9(1):21-24, 2018. (doi: 10.1111/jdi.12718)
  4. Yamane S, Harada N. GIP signaling in adipose tissue. J Diabetes Investig. 10(1):3-5, 2019. (doi: 10.1111/jdi.12942)
  5. Jambaljav B, Tanaka D, Nagashima K, Harashima SI, Harada N, Fujiwara Y, Wang Y, Liu Y, Tabara Y, Matsuda F, Koizumi A, and Inagaki N. Whole-exome sequencing in a Japanese family with highly aggregated diabetes identifies a candidate susceptibility mutation in ADAMTSL3. Diabetes Res Clin Pract. 135:143-149, 2018. (doi: 10.1016/j.diabres.2017.11.012)
  6. Mitsuishi S, Nishimura R, Harashima SI, Kawamura T, Tsujino D, Koide K, Nishimura A, Utsunomiya K, Inagaki N, and Atsumi Y. The Effect of novel glucose monitoring system (flash glucose monitoring) on mental well-being and treatment satisfaction in Japanese people with diabetes. Adv Ther. 35(1):72-80, 2018. (doi: 10.1007/s12325-017-0649-x)
  7. Suzuki K, Iwasaki K, Murata Y, Harada N, Yamane S, Hamasaki A, Shibue K, Joo E, Sankoda A, Fujiwara Y, Hayashi Y, and Inagaki N. Distribution and hormonal characterization of primary murine L-cells throughout the gastrointestinal tract. J Diabetes Investig. 9(1):25-32, 2018. (doi: 10.1111/jdi.12681)
  8. Kadowaki T, Inagaki N, Kondo K, Nishimura K, Kaneko G, Maruyama N, Nakanishi N, Watanabe Y, and Gouda M, Iijima H. Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes. Diabetes Obes Metab. 20(1):77-84, 2018. (doi: 10.1111/dom.13038)
  9. Seko Y, Sumida Y, Sasaki K, Itoh Y, Iijima H, Hashimoto T, Ishii S, and Inagaki N. Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials. J Gastroenterol. 53(1):140-151, 2018. (doi: 10.1007/s00535-017-1364-8)
  10. Kimura H, Ogawa Y, Fujimoto H, Mukai E, Kawashima H, Arimitsu K, Toyoda K, Fujita N, Yagi, Y, Hamamatsu K, Murakami T, Murakami A, Ono M, Nakamoto Y, Togashi K, Inagaki N, and Saji H. Evaluation of 18F-labeled exendin(9-39) derivatives targeting glucagon-like peptide-1 receptor for pancreatic β-cell imaging. Bioorg Med Chem. 26(2):463-469, 2018. (doi: 10.1016/j.bmc.2017.12.007)
  11. Choi J, Kobayashi H, Okuda H, Harada KH, Takeda M, Fujimoto H, Yamane S, Tanaka D, Youssefian S, Inagaki N, and Koizumi A. β-cell-specific overexpression of adiponectin receptor 1 does not improve diabetes mellitus in Akita mice. PLoS ONE. 13(1): e0190863, Jan 5, 2018. (doi: 10.1371/journal.pone.0190863)
  12. Inagaki N, Sano H, Seki Y, Kuroda S, and Kaku K. Efficacy and safety of once-weekly oral trelagliptin switched from once-daily dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: an open-label, phase 3 exploratory study. J Diabetes Investig. 9(2):354-359, 2018. (doi: 10.1111/jdi.12730)
  13. Kadowaki T, Inagaki N, Kondo K, Nishimura K, Kaneko G, Maruyama N, Nakanishi N, Gouda M, Iijima H, and Watanabe Y. Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, placebo-controlled, parallel-group comparative study. Diabetes Obes Metab. 20(2):453-457, 2018. (doi: 10.1111/dom.13079)
  14. Shimazu-Kuwahara S, Kanemaru Y, Harada N, Ikeguchi E, Ueda Y, Yamane S, Murata Y, Yasoda A, Kieffer TJ, Inagaki N. Glucose-dependent insulinotropic polypeptide deficiency reduced fat accumulation and insulin resistance but deteriorated bone loss in ovariectomized mice. The authors contributed equally to this work. J Diabetes Investig. (doi: 10.1111/jdi.12978) [Epub ahead of print]
  15. Hasegawa T, Komagata M, Hamasaki A, Harada N, Seino Y, Inagaki N. Solid-phase extraction treatment is required for measurement of active GLP-1 by ELISA kit affected by heterophilic antibodies. J Diabetes Investig. 10(2):302-308, 2019. (doi: 10.1111/jdi.12896)
  16. Mano F, Ikeda K, Joo E, Yamane S, Harada N, and Inagaki N. Effects of three major amino acids found in Japanese broth on glucose metabolism and gastric emptying. Nutrition 46: 153-158, 2018. (doi: 10.1016/j.nut.2017.08.007)
  17. Yamauchi I, Sakane Y, Yamashita T, Hirota K, Ueda Y, Kanai Y, Yamashita Y, Kondo E, Fujii T, Taura D, Sone M, Yasoda A, and Inagaki N. Effects of growth hormone on thyroid function are mediated by type 2 iodothyronine deiodinase in humans. Endocrine. 59(2):353-363, 2018. (doi: 10.1007/s12020-017-1495-y)
  18. Inagaki N, Harashima SI, Kaku K, Kondo K, Maruyama N, Otsuka M, Kawaguchi Y, and Iijima H. Long-term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 20(4):812-820, 2018. (doi: 10.1111/dom.13152)
  19. Ohno Y, Sone M, Taura D, Yamasaki T, Kojima K, Honda-Kohmo K, Fukuda Y, Matsuo K, Fujii T, Yasoda A, Ogawa O, and Inagaki N. Evaluation of quantitative parameters for distinguishing pheochromocytoma from other adrenal tumors. Hypertens Res. 41(3):165-175, 2018. (doi: 10.1038/s41440-017-0002-4)
  20. Umakoshi H, Ogasawara T, Takeda Y, Kurihara I, Itoh H, Katabami T, Ichijo T, Wada N, Shibayama Y, Yoshimoto T, Ogawa Y, Kawashima J, Sone M, Inagaki N, Takahashi K, Watanabe M, Matsuda Y, Kobayashi H, Shibata H, Kamemura K, Otsuki M, Fujii Y, Yamamto K, Ogo A, Yanase T, Okamura S, Miyauchi S, Suzuki T, Tsuiki M, Naruse M and JPAS Study Group. Accuracy of adrenal computed tomography in predicting the unilateral subtype in young patients with hypokalaemia and elevation of aldosterone in primary aldosteronism. Clin. Endocrol. (Oxf) 88(5):645-651., 2018. (doi: 10.1111/cen.13582)
  21. Umakoshi H, Tsuiki M, Yokomoto-Umakoshi M, Takeda Y, Takashi Y, Kurihara I, Itoh H, Katabami T, Ichijo T, Wada N, Shibayama Y, Yoshimoto T, Ashida K, Ogawa Y, Kawashima J, Sone M, Inagaki N, Takahashi K, Watanabe M, Matsuda Y, Kobayashi H, Shibata H, Kamemura K, Otsuki M, Fujii Y. Yamamto K, Ogo A, Okamura S, Miyauchi S, Fukuoka T, Izawa S, Yanase T, Hashimoto S, Yamada M, Yoshikawa Y, Kai T, Suzuki T, Kawamura T, and Naruse M. Correlation Between Lateralization Index of Adrenal Venous Sampling and Standardized Outcome in Primary Aldosteronism. J Endocr Soc. 2(8):893-902, 2018. (doi: doi: 10.1210/js.2018-00055)
  22. Tanaka H, Nishikawa Y, Fukushima T, Taniguchi A, Fujita Y, Tsuda K, Inagaki N, and Hosokawa M. Lipopolysaccharide inhibits hepatic gluconeogenesis in rats: The role of immune cells. J Diabetes Investig. 9: 494-504, 2018. (doi: 10.1111/jdi.12729)
  23. Fujita N, Yamamoto Y, Hayashino Y, Kuwata H, Okamura S, Iburi T, Furuya M, Kitatani M, Yamazaki S, Ishii H, Tsuji S, Inagaki N, Fukuhara S. Diabetes Distress and Care Registry at Tenri Study Group. Real-life glycemic control in patients with type 2 diabetes treated with insulin therapy: A prospective, longitudinal cohort study (Diabetes Distress and Care Registry at Tenri [DDCRT 9]). J. Diabetes Investig. 9(2):294-302, 2018. (doi: 10.1111/jdi.12693)
  24. Polidori D, Iijima H, Goda M, Maruyama N, Inagaki N, and Ceawford PA. Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin. Diabetes Obes Metab. 20(5):1321-1326, 2018. (doi: 10.1111/dom.13224)
  25. Maekawa R, Ogata H, Murase M, Harada N, Suzuki K, Joo E, Sankoda A, Iida A, Izumoto S, Tsunekawa S, Hamada Y, Oiso Y, Inagaki N, Arima H, Hayashi Y, and Seino Y. Glucose-dependent insulinotropic polypeptide is required for moderate high fat diet, but not high carbohydrate diet-induced weight gain. Am. J. Physiol. Endocrinol Metab. 314(6):E572-E583, 2018. (doi: 10.1152/ajpendo.00352.2017)
  26. Harashima SI, Inagaki N, Kondo K, Maruyama N, Otsuka M, Kawaguchi Y, and Watanabe Y. Efficacy and safety of canagliflozin as add-on therapy to a glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week, open-label, phase IV study. Diabetes Obes Metab. 20(7):1770-1775, 2018. (doi: 10.1111/dom.13267)
  27. Nishimura A. Harashima SI, Hosoda K, and Inagaki N. Long-term effect of the color record method in self-monitoring of blood glucose on metabolic parameters in type 2 diabetes: A 2-year follow-up of the color IMPACT study. Diabetes Ther. 9(4):1501-1510, 2018. (doi: 10.1007/s13300-018-0457-6)
  28. Ikeguchi E, Harada N, Kanemaru Y, Sankoda A, Yamane S, Iwasaki K, Imajo M, Murata Y, Suzuki K, Joo E, and Inagaki N. Transcriptional factor pancreatic duodenal homeobox-1 (Pdx1) is involved in age-related GIP hypersecretion in mice. Am. J. Physiol. Gastrointest Liver Physiol. 315(2):G272-G282, 2018. (doi: 10.1152/ajpgi.00054.2018)
  29. Takeda M, Yamamoto K, Akasaka H, Rakugi H, Naruse M, Takeda Y, Kurihara I, Itoh H, Umakoshi H, Tsuiki M, Ichijo T, Katabami T, Wada N, Shibayama Y, Yoshimoto T, Ogawa Y, Kawashima J, Sone M, Inagaki N, Takahashi K, Fujita M, Watanabe M, Matsuda Y, Kobayashi H, Shibata H, Kamemura K, Otsuki M, Fujii Y, Ogo A, Okamura S, Miyauchi S, Yanase T, Suzuki T, and Kawamura T; JPAS Study Group. Clinical characteristics and postoperative outcomes of primary aldosteronism in the elderly. J Clin Endocrinol Metab. 103: 3620-3629, 2018. (doi: 10.1210/jc.2018-00059)
  30. Kobayashi H, Abe M, Soma M, Takeda Y, Kurihara I, Itoh H, Umakoshi H, Tsuiki M, Katabami T, Ichijo T, Wada N, Yoshimoto T, Ogawa Y, Kawashima J, Sone M, Inagaki N, Takahashi K, Watanabe M, Matsuda Y, Shibata H, Kamemura K, Yanase T, Otsuki M, Fujii Y, Yamamoto K, Ogo A, Nanba K, Tanabe A, Suzuki T, and Naruse M; JPAS Study Group. Development and validation of subtype prediction scores for the workup of primary aldosteronism. J Hypertens. 6(11):2269-2276, 2018. (doi: 10.1097/HJH.0000000000001855)
  31. Usui R, Sakuramachi Y, Seino Yus, Murotani K, Kuwata H, Tatsuoka H, Hamamoto Y, Kurose T, Seino Yut, Yabe D. Reply to the comment of Wilbrink et al. on Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes: The association between remaining β-cell function and the achievement of the HbA1c target 1 year after initiation. J Diabetes Investig. 9(4): 981-983, 2018. (doi: 10.1111/jdi.12858)
  32. Mano F, Ikeda K, Joo E, Fujita Y, Yamane S, Harada N and Inagaki N. The Effect of White Rice and White Bread as Staple Foods on Gut Microbiota and Host Metabolism. Nutrients. 10(9). pii: E1323, 2018. (doi:org/10.3390/nu10091323)
  33. Ohno Y, Sone M, Inagaki N, Yamasaki T, Ogawa O, Takeda Y, Kurihara I, Itoh H, Umakoshi H, Tsuiki M, Ichijo T, Katabami T, Tanaka Y, Wada N, Shibayama Y, Yoshimoto T, Ogawa Y, Kawashima J, Takahashi K, Fujita M, Watanabe M, Matsuda Y, Kobayashi H, Shibata H, Kamemura K, Otsuki M, Fujii Y, Yamamoto K, Ogo A, Okamura S, Miyauchi S, Fukuoka T, Izawa S, Yoneda T, Hashimoto S, Yanase T, Suzuki T, Kawamura T, Tabara Y, Matsuda F, Naruse M; Nagahama Study; JPAS Study Group. Prevalence of Cardiovascular Disease and Its Risk Factors in Primary Aldosteronism: A Multicenter Study in Japan. Hypertension. 71(3):530-537,2018. (doi: 10.1161/HYPERTENSIONAHA.117.10263)
  34. Ohno Y, Sone M, Taura D, Yamasaki T, Kojima K, Honda-Kohmo K, Fukuda Y, Matsuo K, Fujii T, Yasoda A, Ogawa O, Inagaki N. Evaluation of quantitative parameters for distinguishing pheochromocytoma from other adrenal tumors. Hypertens Res. 41(3):165-175,2018. (doi: 10.1038/s41440-017-0002-4)
  35. Hirota K, Yasoda A, Kanai Y, Ueda Y, Yamauchi I, Yamashita T, Sakane Y, Fujii T and Inagaki N. Live imaging analysis of the growth plate in a murine long bone explanted culture system. Sci Rep. 8(1):10332, 2018. (doi: 10.1038/s41598-018-28742-x)
  36. Hirota K, Furuya M, Morozumi N, Yoshikiyo K, Yotsumoto T, Jindo T, Nakamura R, Murakami K, Ueda Y, Hanada T, Sade H, Yoshida S, Enomoto K, Kanai Y, Yamauchi I, Yamashita T, Ueda-Sakane Y, Fujii T, Yasoda A, Inagaki N. Exogenous C-type natriuretic peptide restores normal growth and prevents early growth plate closure in its deficient rats. PLoS One. 13(9):e0204172, 2018. (doi: 10.1371/journal.pone.0204172)
  37. Ikeda K, Fujimoto S, Morling B, Ayano-Takahara S, Harashima SI, Uchida Y, Inagaki N. Cross-cultural comparison of predictors for self-care behaviors in patients with type 2 diabetes. J Diabetes Investig. 9(5): 1212-1215, 2018. (doi: 10.1111/jdi.12822)
  38. Ikeda K, Sato T, Nakayama T, Tanaka D, Nagashima K, Mano F, Joo E, Fujimoto S, Takahashi Y, Kosugi S, Sekine A, Tabara Y, Matsuda F, Inagaki N. Dietary habits associated with reduced insulin resistance: The Nagahama Study. Diabetes Res Clin Pract. 141:26-34, 2018. (doi: 10.1016/j.diabres.2018.04.006)
  39. Yabe D, Yasui A, Ji L, Lee MK, Ma RCW, Chang TJ, Okamura T, Zeller C, Kaspers S, Lee J, Kohler S, Seino Y. Safety and tolerability of empagliflozin in East Asian patients type 2 diabetes: pooled analysis of Phase I III clinical trials. J Diabetes Investig. 10(2):418-428, 2018. (doi: 10.1111/jdi.12910)
  40. Tanaka N, Yabe D, Murotani K, Ueno S, Kuwata H, Hamamoto Y, Kurose T, Takahashi N, Akashi T, Matsuoka T, Osonoi T, Minami M, Shimono D, Seino Y, The Positive SMBG Study Group Investigators. Mental distress and health-related quality of life among type 1 and type 2 diabetes patients using self-monitoring of blood glucose: A cross-sectional questionnaire study in Japan. J Diabetes Investig. 9(5):1203-1211, 2018. (doi: 10.1111/jdi.12827)
  41. Kuwata H, Okamoto S, Seino Y, Murotani K, Tatsuoka H, Usui R, Hamamoto Y, Kurose T, Seino Y, Yabe D. Relationship between deterioration of HbA1c-lowering effects in DPP-4 inhibitor monotherapy and dietary habits: Retrospective analysis of Japanese individuals with type 2 diabetes. J Diabetes Investig. 9(5):1153-1158, 2018. (doi: 10.1111/jdi.12779)
  42. Bentley NL, Fiveash CE, Osborne B, Quek LE, Ogura M, Inagaki N, Cooney GJ, Polly P, Montgomery MK, Turner N. Protein hypoacylation induced by Sirt5 overexpression has minimal metabolic effect in mice. Biochem Biophys Res Commun. 503(3):1349-1355, 2018. (doi: 10.1016/j.bbrc.2018.07.047)
  43. Hamamatsu K, Fujimoto H, Fujita N, Murakami T, Kimura H, Saji H, Inagaki N. Establishment of a method for in-vivo SPECT/CT imaging analysis of 111In-labeled exendin-4 pancreatic uptake in mice without the need for nephrectomy or a secondary probe. Nucl Med Biol. 64-65:22-27, 2018. (doi: 10.1016/j.nucmedbio.2018.06.002)
  44. Ohno Y, Sone M, Inagaki N, Yamasaki T, Ogawa O, Takeda Y, Kurihara I, Umakoshi H, Ichijo T, Katabami T, Wada N, Ogawa Y, Yoshimoto T, Kawashima J, Watanabe M, Matsuda Y, Kobayashi H, Shibata H, Miyauchi S, Kamemura K, Fukuoka T, Yamamoto K, Otsuki M, Suzuki T, and Naruse M, for the JPAS Study Group. Obesity as a Key Factor Underlying Idiopathic Hyperaldosteronism. J Clin Endocrinol Metab. 103(12):4456 4464, 2018. (doi: 10.1210/jc.2018-00866)
  45. Mano F, Ikeda K, Sato T, Nakayama T, Tanaka D, Joo E, Takahashi Y, Kosugi S, Sekine A, Tabara Y, Matsuda F, Inagaki N, on behalf of the Nagahama Study Group. Reduction in Gastroesophageal Reflux Disease Symptoms Is Associated with Miso Soup Intake in a Population-Based Cross-Sectional Study: The Nagahama Study. J Nutr Sci Vitaminol. 64(5):367-373, 2018.  (doi: 10.3177/jnsv.64.367)
  46. Suzuki N, Goto Y, Ota H, Kito K, Mano F, Joo E, Ikeda K, Inagaki N, Nakayama T. Characteristics of the Japanese diet described in epidemiologic publications: A qualitative systematic review. J Nutr Sci Vitaminol. 64(2): 129-137, 2018. (doi: 10.3177/jnsv.64.129)
  47. Goto H, Nishio M, To Y, Oishi T, Miyachi Y, Maehama T, Nishina H, Akiyama H, Mak TW, Makii Y, Saito T, Yasoda A, Tsumaki N, Suzuki A. Loss of Mob1a/b in mice results in chondrodysplasia due to YAP1/TAZ-TEAD-dependent repression of SOX9. Development. 2018 Mar 16;145(6). (doi: 10.1242/dev.159244)
  48. Watanabe M, Nakamoto Y, Koyasu S, Ishimori T, Yasoda A, Togashi K. The influence of elevated hormone levels on physiologic accumulation of 68Ga-DOTATOC. Ann Nucl Med. 2018 Apr;32(3):191-196. (doi: 10.1007/s12149-018-1233-4)
  49. Miyazaki T, Otani K, Chiba A, Nishimura H, Tokudome T, Takano-Watanabe H, Matsuo A, Ishikawa H, Shimamoto K, Fukui H, Kanai Y, Yasoda A, Ogata S, Nishimura K, Minamino N, Mochizuki N. A New Secretory Peptide of Natriuretic Peptide Family, Osteocrin, Suppresses the Progression of Congestive Heart Failure After Myocardial Infarction. Circ Res. 2018 Mar 2;122(5):742-751. (doi: 10.1161/CIRCRESAHA.117.312624)
  50. Ikeguchi E, Harada N, Kanemaru Y, Sankoda A, Yamane S, Iwasaki K, Imajo M, Murata Y, Suzuki K, Joo E, Inagaki N. Transcriptional factor Pdx1 is involved in age-related GIP hypersecretion in mice. Am J Physiol Gastrointest Liver Physiol. 315(2): G272-G282, 2018. (doi: 10.1152/ajpgi.00054.2018)
  51. Kato T, Tanaka D, Muro S, Jambaljav B, Mori E, Yonemitsu S, Oki S, Inagaki N. A Novel p.L145Q Mutation in the HNF1B Gene in a Case of Maturity-onset Diabetes of the Young Type5(MODY5). Intern Med. 57:2035-2039, 2018. (doi: 10.2169/internalmedicine.9692-17)
  52. Sugawa T, Murakami T, Yabe D, Kashima R, Tatsumi M, Ooshima S, Joo E, Wada K, Yoshizawa A, Masui T, Nakamoto Y, Yamauchi Y, Kodama Y, Iemura Y, Ogura M, Yasoda A, Inagaki N. Hypoglycemia Unawareness in Insulinoma revealed with Flash Glucose Monitoring. Intern Med.. 57:3407-3412, 2018. (doi: 10.2169/internalmedicine.1173-18)
  53. Murakami T, Yabe D, Inagaki N. Case 23-2018: A Man with Episodes of Confusion and Hypoglycemia. N Engl J Med. 379(19):1881-1882, 2018. (doi: 10.1056/NEJMc1811310)
  54. Yoshiji S, Murakami, T, Harashima, SI, Ko R, Kashima R, Yabe D, Ogura M, Doi K, and Inagaki N. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors: A report of five cases. J Diabetes Investig. 9(2):445-447, 2018. (doi: 10.1111/jdi.12695)